Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

ribose/悪性腫瘍

リンクがクリップボードに保存されます
ページ 1 から 148 結果

Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma

登録ユーザーのみが記事を翻訳できます
ログインサインアップ

The Safety and Efficacy Study of RiaGev in Healthy Adults

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Nicotinamide adenine dinucleotide (NAD+) is one of the essential cofactors required for the proper function of living cells, and depletion in NAD has been correlated to aging individuals as NAD is associated with oxidative stress and energy production. Per the Population Reference Bureau (PRB), it
PRIMARY OBJECTIVES: I. To compare radiographic progression-free survival (rPFS) and overall survival (OS) with enzalutamide and rucaparib camsylate (rucaparib) versus enzalutamide alone for patients with metastatic castration resistant prostate cancer commencing first-line therapy. II. (PK substudy)

A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Cervical cancer is the 4th most prevalent female cancer worldwide. In the UK there are around 3,207 new cases each year (2013) and 890 deaths (2012) (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-t ype/cervical-cancer). It is the most common cancer in

NUVOLA TRIAL Open-label Multicentre Study

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
This is a Phase II, randomised, multicentre study to investigate the efficacy and tolerability of a second maintenance treatment in participants with PSR epithelial ovarian cancer, who have previously received PARPi maintenance treatment and who have benefit (CR or PR) or SD from further platinum

Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
This is an open-label, single-arm study in which patients with HER2-expressing locally advanced or metastatic solid tumours will be treated with both an anti-body drug conjugate SYD985 and a Poly (ADP-ribose) Polymerase (PARP) inhibitor niraparib. SYD985 is an antibody-drug conjugate and consists of
PRIMARY OBJECTIVE: I. Estimate the progression-free survival (PFS) time. SECONDARY OBJECTIVES: I. Estimate the day 100 non-relapse mortality (NRM) of allogeneic stem cell transplantation (allo SCT) using vorinostat/gemcitabine/clofarabine/busulfan (SAHA/Gem/Clo/Bu) with post-transplant

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Background: - We hypothesize that a dose-escalation strategy that incorporates tumor targeted DNA- damaging chemotherapy and DNA-damage response (DDR) inhibitors could allow safe and effective administration of DDR inhibitor-chemotherapy combination. - PLX038 is a PEGylated conjugate of SN38 with

Niraparib/TTFields in GBM

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Tumor-treating fields (TTFields) causes downregulation of BRCA1 signaling and reduced deoxyribonucleic acid (DNA) double-strand break repair capacity. Tumors that are deficient in the homologous recombination DNA damage repair pathway are highly sensitive to blockade of the repair of single strand
PRIMARY OBJECTIVES: I. To determine the safety and tolerability of olaparib in sequential treatment with adavosertib (AZD1775). II. To establish the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of this sequential schedule in patients with advanced solid tumors in a post-poly adenosine
With the development of cost effective and rapid technology of genome sequencing, precision medicine becomes a new way to think oncology. Current targets involve mainly tyrosine kinase, but DNA repair machinery could also be targetable. Some of DNA repair aberrations have been associated with

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
The primary, secondary, and exploratory objective are to assess the safety of the combination of M4344 and Niraparib in a phase 1 trial of patients with PARP resistant recurrent ovarian cancer; to determine the response rate and percentage of participants who remain progression free survival (PFS)

Trial of Maintenance With Niraparib- Uterine Serous Carcinoma

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Uterine serous carcinoma (USC) accounts for up to 40% of endometrial cancer-related deaths. In contrast to the more common endometrioid histology, USC is more likely to present in advanced stage and carries a worse prognosis. USC mimics the most common serous carcinoma of the ovary and has high

CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Triple-negative breast cancer refers to breast cancer with negative human epidermal growth factor receptor 2, estrogen receptor and progesterone receptor. Triple-negative breast cancer has poor differentiation, high invasiveness and high recurrence rate, accounting for 15.0%-23.8% of breast cancer.
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge